Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR and Everolimus in Lung and Thymus Neuroendocrine Carcinoma
NCT01563354Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Feb 2020
- Modality
- Peptides, Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of pasireotide LAR in neuroendocrine carcinoma of the lung, neuroendocrine carcinoma of the thymus, sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
neuroendocrine carcinoma of the lungneuroendocrine carcinoma of the thymus
Beyond the preview
Go deeper on NCT01563354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563354.